Historical Multi-year Revenue GrowthSustained multi-year revenue expansion indicates the company has grown market share or broadened product adoption. A larger revenue base supports scale economies, long-term investment in manufacturing and distribution, and provides a buffer to fund strategic initiatives despite short-term profit pressure.

Generally Sound Balance SheetA stable equity base and moderate leverage give the company financial flexibility to fund operations, capex and R&D without immediate refinancing risk. This durability helps the firm withstand industry cycles and supports longer-term strategic choices such as capacity expansion or targeted M&A.

Operating Cash Flow RecoveryImproving operating cash flow signals better conversion of earnings to cash from core operations, enhancing liquidity and internal funding capacity. Over a multi-month to multi-year horizon this helps reduce reliance on external financing and supports sustainable investment and working-capital needs.

Bears Say

Margin Compression And Profit DeclineCompressed gross and net margins reduce retained earnings and constrain the firm's ability to reinvest in growth or absorb cost shocks. If driven by structural pricing or cost pressures, sustained margin erosion will materially weaken long-term profitability and return on capital.

Volatile, Negative Free Cash Flow TrendPersistent free cash flow volatility and recent negative trends threaten liquidity and the capacity to fund capex or repay debt from operations. Over several months this raises the likelihood of relying on external financing, increasing financing costs and limiting strategic flexibility.

Slightly Rising Leverage RiskA declining equity ratio indicates growing leverage relative to equity, which reduces financial resilience. In a capital-intensive pharma environment higher leverage increases interest burden and vulnerability to revenue shocks, constraining investment and raising balance-sheet risk over time.

Bafna Pharmaceuticals Limited News

Bafna Pharmaceuticals Files SEBI Dematerialisation Compliance Certificate for Q3 FY2025

Bafna Pharmaceuticals Limited ( ($IN:BAFNAPH) ) has shared an update. Bafna Pharmaceuticals Limited has submitted to the stock...

2M ago

Bafna Pharmaceuticals Completes Sale of Chennai Manufacturing Unit

An update from Bafna Pharmaceuticals Limited ( ($IN:BAFNAPH) ) is now available. Bafna Pharmaceuticals Limited has completed the...

8M ago

Bafna Pharmaceuticals Submits Annual SEBI Disclosure

Bafna Pharmaceuticals Limited ( ($IN:BAFNAPH) ) has shared an update. Bafna Pharmaceuticals Limited has submitted its annual disclosure...

8M ago

Bafna Pharmaceuticals Announces Board and Committee Restructuring

The latest update is out from Bafna Pharmaceuticals Limited ( ($IN:BAFNAPH) ). Bafna Pharmaceuticals Limited announced the retirement...

8M ago

BAFNAPH FAQ

What was Bafna Pharmaceuticals Limited’s price range in the past 12 months?

Bafna Pharmaceuticals Limited lowest stock price was ₹71.65 and its highest was ₹204.95 in the past 12 months.

What is Bafna Pharmaceuticals Limited’s market cap?

Bafna Pharmaceuticals Limited’s market cap is ₹2.74B.

When is Bafna Pharmaceuticals Limited’s upcoming earnings report date?

Bafna Pharmaceuticals Limited’s upcoming earnings report date is Jun 03, 2026 which is in 100 days.

How were Bafna Pharmaceuticals Limited’s earnings last quarter?

Bafna Pharmaceuticals Limited released its earnings results on Feb 11, 2026. The company reported ₹0.776 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.776.

Is Bafna Pharmaceuticals Limited overvalued?

According to Wall Street analysts Bafna Pharmaceuticals Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bafna Pharmaceuticals Limited pay dividends?

Bafna Pharmaceuticals Limited pays a Notavailable dividend of ₹0.6 which represents an annual dividend yield of N/A. See more information on Bafna Pharmaceuticals Limited dividends here

What is Bafna Pharmaceuticals Limited’s EPS estimate?

Bafna Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Bafna Pharmaceuticals Limited have?

Bafna Pharmaceuticals Limited has 23,656,336 shares outstanding.

What happened to Bafna Pharmaceuticals Limited’s price movement after its last earnings report?

Bafna Pharmaceuticals Limited reported an EPS of ₹0.776 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.563%.

Which hedge fund is a major shareholder of Bafna Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in IN:BAFNAPH

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company provides delayed and sustained release, chewable, and orally disintegrating tablets. It also exports its products. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India.